Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what recent progress he has made on monitoring the effectiveness of the (a) Pfizer/BioNTech and (b) Oxford University/AstraZeneca vaccines on people who are immunocompromised.

Public Health England is monitoring the impact of COVID-19 vaccines on a broad range of outcomes including symptomatic disease, infection and hospitalisations as set out in the COVID-19 vaccine surveillance strategy

Vaccine effectiveness assessments are reported regularly to the Joint Committee on Vaccination and Immunisation (JCVI) to inform vaccine policy recommendations. This will include assessment of vaccine effectiveness in immunocompromised individuals using general practice’s electronic health record data. Once sufficient evidence becomes available the JCVI will consider options for a protection strategy for immunosuppressed individuals, including whether any specific vaccine is preferred in this population.